Peer-reviewed

Incidence, Types, and Lifetime Risk of Adult-Onset Strabismus – Corrected Proof

by  • 

Objective: To describe the incidence and types of adult-onset strabismus in a geographically defined population.Design: Retrospectively reviewed population-based cohort.Participants: All adult (≥19 years of age) residents of Olmsted County, Minnesota, diagnosed with new-onset adult strabismus from January 1, 1985, through December 31, 2004.Methods: The medical records of all potential cases identified by the resources of the Rochester Epidemiology Project were reviewed.Main Outcome Measures: Incidence rates for adult-onset strabismus and its types.Results: Seven hundred fifty-three cases of new-onset adult strabismus were identified during the 20-year period, yielding an annual age- and gender-adjusted incidence rate of 54.1 cases (95% confidence interval, 50.2–58.0) per (Read more...)

Peer-reviewed

RADIANCE: A Randomized Controlled Study of Ranibizumab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia – Corrected Proof

by  • 

Objective: To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity (VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) in patients with visual impairment due to myopic choroidal neovascularization (CNV).Design: Phase III, 12-month, randomized, double-masked, multicenter, active-controlled study.Participants: Patients (N = 277) with visual impairment due to myopic CNV.Methods: Patients were randomized to receive ranibizumab on day 1, month 1, and thereafter as needed guided by VA stabilization criteria (group I, n = 106); ranibizumab on day 1 and thereafter as needed guided by disease activity criteria (group II, n = 116); or vPDT on day (Read more...)